Table 1.
Patients' characteristics (n = 42).
| Factor | Number |
|---|---|
| Age | |
| Median (range) | 70 (48–80) |
| Gender | |
| Male | 34 |
| Female | 8 |
| ECOG performance status | |
| 0 | 32 |
| 1 | 10 |
| HLA type | |
| A24 | 24 |
| A2 | 21 |
| A3 supertype | 14 |
| A26 | 13 |
| Clinical stage | |
| IVa | 15 |
| IVb | 27 |
| JIS score | |
| 3 | 21 |
| 4 | 18 |
| 5 | 3 |
| Previously conducted treatments | |
| Locoregional | |
| Hepatectomy | 14 |
| Surgery other than hepatectomy | 2 |
| Radiation | 9 |
| Transcatheter arterial embolization (TAE) | 23 |
| Transcatheter arterial chemoembolization (TACE) | 16 |
| Hepatic arterial infusion chemotherapy (HAIC) | 16 |
| Radiofrequency ablation (RFA) | 15 |
| Percutaneous ethanol injection therapy (PEIT) | 6 |
| Microwave coagulation therapy (MCT) | 3 |
| Systemic | |
| Sorafenib | 21 |
| 5-FU based chemotherapies | 6 |
| Other clinical trials | 9 |
| AFP at first visit | |
| Median (range), ng/mL | 376 (3.7–103000) |
| DCP at first visit | |
| Median (range), mAU/mL | 2335 (11–778000) |
| Number of vaccinations | |
| Median (range) | 8 (3–8) |
| Combination therapy | |
| None | 30 |
| Sorafenib | 10 |
| Chemotherapy | 2 |
ECOG: Eastern Cooperative Oncology Group; JIS: Japanese integrated staging; AFP: α-fetoprotein; DCP: des-γ-carboxy prothrombin.